Navigating the Paradox: Why Genmab's Stock Dipped Despite Positive News for its Key Partnership

The Talc Tempest: Johnson & Johnson Faces Cancer Claims and Billions in Legal Battles

Johnson & Johnson Considers Major Orthopedic Business Split

Carvykti's Q3 Performance: Legend Biotech Navigates Sales Landscape

Johnson & Johnson Soars: Q3 Earnings Crush Expectations, Full-Year Forecast Skyrockets!

Johnson & Johnson's Bold Orthopedics Spin-Off: A New Era of Growth and Value Unveiled

Johnson & Johnson Soars Past Expectations with Stellar Q3 Earnings, Driven by Pharmaceutical and MedTech Growth

Johnson & Johnson Soars: Beating Q3 Expectations and Raising Full-Year Outlook

J&J's Q3 Rollercoaster: Stock Dip, MedTech Hopes, and Tariff Tangles!

The S&P 500's Moment of Truth: Why the 20-Day Moving Average is the Market's Next Big Test

Healthcare Giants Soar: Novo Nordisk, Bristol Myers Squibb, and J&J Lead the Week's Breakthroughs

Wall Street Reacts: Top Stock Moves and Analyst Insights Shaping Thursday's Market

The Billions at Stake: Johnson & Johnson's Decisive Move in Talc Litigation

The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?

Is Pharma Poised for a Powerful Rebound? Chart Master Sees a Major Breakout Ahead

Navigating the AI Stock Landscape: Smart Bets Beyond the Hype, According to Trivariate

Unleash Your Potential: Johnson & Johnson's 'Dual Control' Empowers IBD Patients in Asia Pacific

Navigating the Storm: 20 Defensive Dividend Stocks to Weather a Government Shutdown

Pharma's Unseen Shift: Citi's Meacham Reveals Deep-Rooted U.S. Investment Promises Already Underway

Kenvue's Rollercoaster: How Tylenol Maker's Shares Defied Trump's Autism Claims

Tylenol's Triumphant Rebound: How Scientific Truth Silenced Unfounded Claims and Propelled J&J's Stock

Tylenol Defies Misinformation: Johnson & Johnson Stock Rebounds After Trump's Unfounded Claims

Kenvue Stock Plummets Amid Tylenol Autism Lawsuit & Trump's Fiery Call to Arms

The Tylenol-Autism Controversy: Unpacking the Claims and Legal Battles

The Lingering Question: Is Tylenol Use During Pregnancy Linked to Autism and ADHD?

Tylenol Under Scrutiny: Autism Link Fears Rock Kenvue & J&J Shares

Unlocking Your Cash Potential: UBS's Post-Fed Rate Cut Strategy Revealed

Healthcare Titan UnitedHealth Group Poised for Explosive Growth: Why This Giant Is Building a Foundation for Sharp Gains

Kenvue Explores 'Learned Intermediary' Defense Amidst Thousands of Tylenol-Autism Lawsuits

A New Horizon in Bladder Cancer Treatment: J&J's Balversa Secures Full FDA Approval

FDA Greenlights J&J's Groundbreaking Bladder Cancer Therapy, Offering New Hope

Game Changer: FDA Approves Johnson & Johnson's TAR-200 for High-Risk Bladder Cancer

Kenvue's Tylenol Turmoil: RFK Jr.'s Autism Report Sends Stock Reeling Amidst Scientific and Legal Battles

Fortifying Your Portfolio: 5 Unstoppable Stocks Built to Conquer a Housing Slump

Jim Cramer's Power Play: Navigating the Market's Fed-Fueled Ascent

Johnson & Johnson Unveils Staggering $2 Billion Investment to Supercharge American Manufacturing Amidst Tariff Tensions